Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 12, 2024
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma
Filippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
The Annals of Thoracic Surgery
|
December 17, 2020
Safety and Feasibility of Thoracic Malignancy Surgery During the COVID-19 Pandemic
Joseph Seitlinger, Christophe Wollbrett, Antonio Mazzella, et al.
Journal of Extracellular Vesicles
|
August 11, 2023
Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis
Xin Su, Ariane Brassard, Alexandra Bartolomucci, et al.
The Annals of Thoracic Surgery
|
February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Elizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Cancer
|
May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol
Biniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
Nature Medicine
|
May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
Tina Cascone, Laura Bonanno, Florian Guisier, et al.
Nature Medicine
|
October 30, 2023
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, et al.
Nature Communications
|
September 14, 2021
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria
Yibo Xue, Jordan L Morris, Kangning Yang, et al.
Nature Communications
|
March 22, 2023
Author Correction: SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria
Yibo Xue, Jordan L Morris, Kangning Yang, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 12, 2024
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma
Filippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
The Annals of Thoracic Surgery
|
December 17, 2020
Safety and Feasibility of Thoracic Malignancy Surgery During the COVID-19 Pandemic
Joseph Seitlinger, Christophe Wollbrett, Antonio Mazzella, et al.
Journal of Extracellular Vesicles
|
August 11, 2023
Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis
Xin Su, Ariane Brassard, Alexandra Bartolomucci, et al.
The Annals of Thoracic Surgery
|
February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Elizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Cancer
|
May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol
Biniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
Nature Medicine
|
May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
Tina Cascone, Laura Bonanno, Florian Guisier, et al.
Nature Medicine
|
October 30, 2023
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, et al.
Nature Communications
|
September 14, 2021
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria
Yibo Xue, Jordan L Morris, Kangning Yang, et al.
Nature Communications
|
March 22, 2023
Author Correction: SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria
Yibo Xue, Jordan L Morris, Kangning Yang, et al.
Page
of 10